Pre-treatment peripheral absolute monocyte count predicts metastatic progression and survival outcomes in treatment-naive non-metastatic nasopharyngeal carcinoma
Pre-treatment peripheral AMC ≥0.63×10<sup>9</sup>/L could serve as an independent predictor of metastatic progression, particularly bone metastasis, and reduced survival in treatment-naive, non-metastatic NPC. Being easily obtainable via routine complete blood count, AMC provides significant prognostic value to enhance clinical risk stratification and guide individualized treatment planning.
Authors
- Shuopo Fang
- Xu Cai (ORCID: https://orcid.org/0009-0005-2154-5426)
- Guodong Qiu
- Fen Cai
- Jianfeng Cai
Institutions
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.3389/fonc.2026.1696050
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00